Compare PYXS & EHTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PYXS | EHTH |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.2M | 104.0M |
| IPO Year | 2021 | 2006 |
| Metric | PYXS | EHTH |
|---|---|---|
| Price | $2.01 | $1.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $7.00 | $3.33 |
| AVG Volume (30 Days) | ★ 493.6K | 332.4K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.03 | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | $13,858,000.00 | ★ $251,395,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,043.98 | $5.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 45.86 |
| 52 Week Low | $0.97 | $1.20 |
| 52 Week High | $5.55 | $5.89 |
| Indicator | PYXS | EHTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 47.72 |
| Support Level | $1.58 | $1.64 |
| Resistance Level | $2.17 | $1.72 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 92.45 | 51.54 |
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.